# When the second comes first– rhabdomyosarcoma preceding heritable retinoblastoma– a case report

**Authors:** Devjyoti Tripathy, Alexandre Moulin, Jacques Bijon, Carole Gengler, Maja Beck-Popovic, Francis L. Munier, Christina Stathopoulos

PMC · DOI: 10.1186/s12886-024-03307-x · BMC Ophthalmology · 2024-01-30

## TL;DR

A rare case is reported where rhabdomyosarcoma appeared before heritable retinoblastoma in a child, challenging typical disease progression patterns.

## Contribution

This case report highlights an atypical sequence of tumor manifestation in a heritable retinoblastoma patient.

## Key findings

- Rhabdomyosarcoma preceded the diagnosis of heritable retinoblastoma in a monozygotic twin.
- The child developed metastatic rhabdomyosarcoma and succumbed despite treatment.
- This case reverses the usual timeline of second primary tumors in heritable retinoblastoma survivors.

## Abstract

Retinoblastoma (rb) is the most frequent intraocular tumor, accounting for 3% of all childhood cancers. Heritable rb survivors are germline carriers for an RB1 mutation and have a lifelong risk to develop non-ocular second primary tumors (SPTs) involving multiple other organs like the bones, soft tissues, or skin. These SPTs usually become manifest several years succeeding the diagnosis of rb. In our instance, however, a non-ocular SPT presented prior to the diagnosis of heritable rb.

We report a rare case of a monozygotic twin who presented with primary rhabdomyosarcoma (RMS) preceding the manifestation of heritable rb. The rb was diagnosed when the child developed strabismus while already on therapy for the RMS. The child underwent therapy for both as per defined treatment protocols. The rb regressed well on treatment, but the RMS relapsed and the child developed multiple refractory metastatic foci and succumbed to his disease.

Non-ocular SPTs like sarcomas are usually known to manifest in heritable rb survivors with a lag of two to three decades (earlier if exposure to radiation is present) from the presentation of the rb. However, in our case, this seemed to be reversed with the RMS being manifest at an unusual early age and the rb being diagnosed at a later point in time.

## Linked entities

- **Diseases:** retinoblastoma (MONDO:0008380), rhabdomyosarcoma (MONDO:0005212)

## Full-text entities

- **Genes:** PAX3 (paired box 3) [NCBI Gene 5077] {aka CDHS, HUP2, PAX-3, WS1, WS3}, FOXO1 (forkhead box O1) [NCBI Gene 2308] {aka FKH1, FKHR, FOXO1A}, FMOD (fibromodulin) [NCBI Gene 2331] {aka FM, SLRR2E}, CTSG (cathepsin G) [NCBI Gene 1511] {aka CATG, CG}, PAX7 (paired box 7) [NCBI Gene 5081] {aka CMYO19, CMYP19, HUP1, MYOSCO, PAX7B, RMS2}, RB1 (RB transcriptional corepressor 1) [NCBI Gene 5925] {aka OSRC, PPP1R130, RB, p105-Rb, p110-RB1, pRb}
- **Diseases:** SPTs (MESH:D016609), melanoma (MESH:D008545), sarcoma (MESH:D012509), eye strabismus (MESH:D013285), Retinoblastoma (rb (MESH:D012175), RMS metastases (MESH:D009362), OD (OMIM:165800), osteosarcoma (MESH:D012516), MIT (MESH:D009369), embryonal RMS (MESH:D018233), RMS (MESH:D012208), OS (MESH:C567932), intraocular tumor (MESH:D064090), deformations (MESH:D009140), Alveolar RMS (MESH:D018232)
- **Chemicals:** cyclophosphamide (MESH:D003520), hematoxylin (MESH:D006416), vinblastine (MESH:D014747), eosin (MESH:D004801), carboplatin, doxorubicin, vincristine, ifosfamide (-), melphalan (MESH:D008558)
- **Species:** Homo sapiens (human, species) [taxon 9606]
- **Mutations:** p.(Thr377 Leufs*3), c.1128-1G > A

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC10826275/full.md

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC10826275/full.md

## References

7 references — full list in the complete paper: https://tomesphere.com/paper/PMC10826275/full.md

---
Source: https://tomesphere.com/paper/PMC10826275